Celgene Corp (CELG)

123.97
1.20 0.98
NASDAQ : Health Care
Prev Close 125.20
Open 122.48
Day Low/High 122.12 / 124.98
52 Wk Low/High 92.98 / 137.54
Volume 4.63M
Avg Volume 3.63M
Exchange NASDAQ
Shares Outstanding 777.97M
Market Cap 97.65B
EPS 2.60
P/E Ratio 50.41
Div & Yield N.A. (N.A)

Latest News

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Celgene Reports First Quarter 2017 Operating And Financial Results

Celgene Reports First Quarter 2017 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,950 million for the first quarter of 2017, an 18 percent increase from the same period in 2016.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.

Chart of the Day: Celgene

This stock is poised for more upside.

Intermediate Trade: Celgene

Intermediate Trade: Celgene

I prefer a very short-term, out-of-the-money vertical call spread expiring in May.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Momentum Is Fading

Momentum Is Fading

Forget financials, stick to steady growers.

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Some recent high-flying biotechs may be preparing for their next surge.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Celgene Notified Of ANDA Filing For POMALYST®

Celgene Notified Of ANDA Filing For POMALYST®

Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc.

Celgene Corporation To Announce First Quarter 2017 Results On April 27, 2017

Celgene Corporation To Announce First Quarter 2017 Results On April 27, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.

So Far So Good : Cramer's 'Mad Money' Recap (Friday 3/31/17)

So Far So Good : Cramer's 'Mad Money' Recap (Friday 3/31/17)

The amazing first quarter didn't rely just on Trump.

Getting It Done; Markets Love Seniors: Jim Cramer's Best Blog

Getting It Done; Markets Love Seniors: Jim Cramer's Best Blog

Jim Cramer ponders how Breen is getting it done for DuPont, and discusses why the markets love seniors so gosh darn much.

Halliburton, Schlumberger, Alcoa, Celgene:'Mad Money' Lightning Round (3/29/17)

Halliburton, Schlumberger, Alcoa, Celgene:'Mad Money' Lightning Round (3/29/17)

Jim Cramer is bullish on Halliburton, Schlumberger, Cypress Semiconductor and Celgene

This Market Loves Tech: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)

This Market Loves Tech: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)

Tech's organic growth and visibility has been apparent all year, says Jim Cramer.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

Celgene Has Cure for Market Blues

Celgene Has Cure for Market Blues

Strong biotech stock has surged since November and is close to all-time highs.

Chart of the Day: Celgene

This name is within about 10% of all-time highs.

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

Stocks Extend Declines as Biogen Leads Health Care Selloff

Stocks Extend Declines as Biogen Leads Health Care Selloff

Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.